Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

Beijing’s action against clothing maker PVH and biotech company Illumina underlines risk created by trade tensions ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Nano-X Imaging is a disruptive biotech investment. The AI push in the health sector is a long-term tailwind. See why we rate ...

Concord Biotech tumbled 15.02% to Rs 1,793 after the company's consolidated net profit fell 2.1% to Rs 75.92 crore in Q3 FY25 as compared with Rs 77.57 crore in Q3 FY24.

These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.

Best-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...